Modeyso (dordaviprone) is a protease activator used to treat a rare and aggressive brain tumor called diffuse midline glioma (DMG) with a H3 K27M mutation. It's FDA approved for adults and in children 1 year and older whose cancer has gotten worse after previous treatment. You take it by mouth once a week on an empty stomach. Common side effects include tiredness, headache, and nausea.
Modeyso (dordaviprone) is a protease activator. It turns on a protein called ClpP inside cancer cells, which can trigger cancer cell death and disrupt how the cells make energy.
It also blocks dopamine receptors, which could also help slow cancer cell growth.
When does Modeyso (dordaviprone) start working?Time passed since treatment started:
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
First FDA‑approved treatment for H3 K27M‑mutant DMG
Only need to take once a week
Capsules can be opened and mixed with certain liquids
Safe for young children
Cons
Requires heart and blood tests before and during treatment
Can affect heart rhythm
Interacts with many medications
Not safe in pregnancy
Pharmacist tips for Modeyso (dordaviprone)
Take Modeyso (dordaviprone) on the same day each week on an empty stomach. Take it at least 1 hour before or 3 hours after eating.
If you vomit after taking Modeyso (dordaviprone), don’t take another dose. Take your next dose on your usual scheduled day.
If you miss a dose of Modeyso (dordaviprone) by 1 or 2 days, take it as soon as you remember. If it’s been more than 2 days, skip the missed dose and take your next dose as scheduled.
Modeyso (dordaviprone) can affect your heart rhythm. Your care team will check an electrocardiogram (ECG or EKG) and electrolytes before you start and sometimes during treatment. Tell them right away if you feel dizzy, faint, or notice a fast or irregular heartbeat.
Serious allergic reactions can happen with Modeyso (dordaviprone). Get medical help right away if you have symptoms like rash, swelling, trouble breathing, or severe itching.
Modeyso (dordaviprone) can interact with many medications. Check with your prescriber or pharmacist before starting any new prescription, over-the-counter medication, or supplement.
Pregnancy: Modeyso (dordaviprone) can harm an unborn baby. Use birth control during treatment and for 1 month after your last dose. Call your care team right away if you or your partner become pregnant.
Breastfeeding: Don’t breastfeed while taking Modeyso (dordaviprone) or for 1 week after your last dose.
Storage: Keep Modeyso (dordaviprone) at room temperature in its original bottle. Keep it tightly closed, dry, and out of reach of children and pets.
How to take Modeyso (dordaviprone) if you can’t swallow capsules:
Open the capsules and empty the contents into 1 to 2 tablespoons of water, apple juice, lemonade, or a sports drink. Stir well before taking.
Take all of the mixture within 2 hours of preparing it. Don't save it for later.
After taking your dose, add 1 to 2 more tablespoons (15 to 30 ml) of liquid to the cup and drink it. This helps make sure you get the full dose.
Risks and warnings for Modeyso (dordaviprone)
Modeyso (dordaviprone) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Serious allergic reaction
Modeyso (dordaviprone) can cause serious allergic reactions, although they are rare. Symptoms can include hives, rash, wheezing, swelling of the face or throat, dizziness.
Get medical help right away if you notice any of these symptoms after taking this medication. Your care team might have you stop it and provide treatment for the reaction.
Abnormal heart rhythm
Risk factors: Taking other medications that affect heart rhythm | History of heart rhythm problems | Electrolyte problems | Heart failure | Taking medications that interact with Modeyso (dordaviprone)
Modeyso (dordaviprone) can affect your heart rhythm. In rare cases, this can lead to serious or life-threatening heartbeat problems.
Your care team will check an electrocardiogram (ECG) and electrolytes before you start this medication. They might recheck during treatment, especially if your dose changes or you start medications that interact with Modeyso (dordaviprone). Call your care team or seek urgent care if you faint, feel your heart racing, or have severe dizziness.
Harm to unborn baby
Modeyso (dordaviprone) can harm an unborn baby based on how it works. Because of this risk, women who can become pregnant should use effective birth control during treatment and for 1 month after the last dose.
Men with partners who can become pregnant should also use effective birth control during treatment and for 1 month after the last dose. Tell your care team right away if you or your partner become pregnant while taking this medication.
Modeyso (dordaviprone) dosage
Typical dosage for Modeyso (dordaviprone)
Adults: The typical dose is 625 mg by mouth once weekly.
Children and teens (age 1 to less than 17 years, weighing at least 10 kg)
10 kg to less than 12.5 kg: The typical dose is 125 mg by mouth once weekly.
12.5 kg to less than 27.5 kg: The typical dose is 250 mg by mouth once weekly.
27.5 kg to less than 42.5 kg: The typical dose is 375 mg by mouth once weekly.
42.5 kg to less than 52.5 kg: The typical dose is 500 mg by mouth once weekly.
More than 52.5 kg: The typical dose is 625 mg by mouth once weekly.
Your dose might differ if you have side effects or take other medications that interact with Modeyso (dordaviprone).
Modeyso (dordaviprone) images
This medicine is White Capsule Imprinted With "Cmrx Ddp 125".White Capsule CMRX DDP 125 - MODEYSO 125mg Capsule
GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.
Prescription savings
Stop paying too much for your prescriptions. Compare prices, get pharmacy coupons, and save up to 80%.
Yes, Modeyso was FDA approved in August 2025. It received accelerated approval, which is a special type of approval the FDA uses for serious conditions with limited treatment options. This means early studies showed that Modeyso could help treat diffuse midline glioma (DMG) with an H3 K27M mutation, but more studies are still being done to confirm its long-term benefits.
In studies of people with diffuse midline glioma (DMG) with an H3 K27M mutation, about 22% taking Modeyso had their tumors shrink. Among those who responded, 73% had had tumor shrinkage that lasted longer than 6 months. Because Modeyso received accelerated approval, more studies are still being done to confirm how much it helps people live longer and improves long-term outcomes.
Modeyso doesn’t work right away. In studies, people whose tumors responded to treatment started seeing tumor shrinkage after about 3.6 months, on average. Your care team will monitor you with scans and other tests to see how well the medication is working.